Mar 17, 2016 7:00am EDT Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis
Mar 03, 2016 7:00am EST Can-Fite to Present Psoriasis Data at American Academy of Dermatology's 74th Annual Meeting in Washington D.C. on March 7, 2016
Feb 05, 2016 7:00am EST Can-Fite to Present at BIO CEO & Investor Conference in New York City on February 8, 2016
Jan 25, 2016 7:00am EST Can-Fite CEO Dr. Pnina Fishman to Chair Scientific Session at the 2016 Purinergic Signaling and Cancer Immunotherapy Conference in Vancouver on January 26, 2016
Jan 19, 2016 7:00am EST U.S. Patent & Trademark Office Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602
Jan 11, 2016 7:00am EST Can-Fite Announces 2016 Clinical Milestones for its Pipeline of Drugs in Six Indications
Jan 05, 2016 7:00am EST Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis
Dec 17, 2015 7:00am EST Can-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma
